Literature DB >> 23629604

Barrett oesophagus: Is RFA the overall answer to all Barrett oesophagus issues?

Michael Vieth, Helmut Neumann.   

Abstract

Mesh：

Year:  2013        PMID： 23629604     DOI： 10.1038/nrgastro.2013.75

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  9 in total

1.  [Early Barrett's neoplasia--don't burn without histology].

Authors:  A Behrens; O Pech; C Ell
Journal:  Z Gastroenterol       Date:  2011-09-30       Impact factor: 2.000

2.  Focal endoscopic mucosal resection before radiofrequency ablation is equally effective and safe compared with radiofrequency ablation alone for the eradication of Barrett's esophagus with advanced neoplasia.

Authors:  Hannah P Kim; William J Bulsiewicz; Cary C Cotton; Evan S Dellon; Melissa B Spacek; Xiaoxin Chen; Ryan D Madanick; Sarina Pasricha; Nicholas J Shaheen
Journal:  Gastrointest Endosc       Date:  2012-06-23       Impact factor: 9.427

3.  Durability of radiofrequency ablation in Barrett's esophagus with dysplasia.

Authors:  Nicholas J Shaheen; Bergein F Overholt; Richard E Sampliner; Herbert C Wolfsen; Kenneth K Wang; David E Fleischer; Virender K Sharma; Glenn M Eisen; M Brian Fennerty; John G Hunter; Mary P Bronner; John R Goldblum; Ana E Bennett; Hiroshi Mashimo; Richard I Rothstein; Stuart R Gordon; Steven A Edmundowicz; Ryan D Madanick; Anne F Peery; V Raman Muthusamy; Kenneth J Chang; Michael B Kimmey; Stuart J Spechler; Ali A Siddiqui; Rhonda F Souza; Anthony Infantolino; John A Dumot; Gary W Falk; Joseph A Galanko; Blair A Jobe; Robert H Hawes; Brenda J Hoffman; Prateek Sharma; Amitabh Chak; Charles J Lightdale
Journal:  Gastroenterology       Date:  2011-05-06       Impact factor: 22.682

4.  Safety of prior endoscopic mucosal resection in patients receiving radiofrequency ablation of Barrett's esophagus.

Authors:  Ngozi I Okoro; Yutaka Tomizawa; Kelly T Dunagan; Lori S Lutzke; Kenneth K Wang; Ganapathy A Prasad
Journal:  Clin Gastroenterol Hepatol       Date:  2011-11-02       Impact factor: 11.382

5.  Circumferential and focal ablation of Barrett's esophagus containing dysplasia.

Authors:  Virender K Sharma; H Jae Kim; Ananya Das; Christopher D Wells; Cuong C Nguyen; David E Fleischer
Journal:  Am J Gastroenterol       Date:  2009-01-27       Impact factor: 10.864

6.  Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett's esophagus: results from a US Multicenter Consortium.

Authors:  Milli Gupta; Prasad G Iyer; Lori Lutzke; Emmanuel C Gorospe; Julian A Abrams; Gary W Falk; Gregory G Ginsberg; Anil K Rustgi; Charles J Lightdale; Timothy C Wang; David I Fudman; John M Poneros; Kenneth K Wang
Journal:  Gastroenterology       Date:  2013-03-15       Impact factor: 22.682

7.  Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett's esophagus with radiofrequency ablation.

Authors:  Eric S Orman; Hannah P Kim; William J Bulsiewicz; Cary C Cotton; Evan S Dellon; Melissa B Spacek; Xiaoxin Chen; Ryan D Madanick; Sarina Pasricha; Nicholas J Shaheen
Journal:  Am J Gastroenterol       Date:  2012-12-18       Impact factor: 10.864

8.  Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry.

Authors:  Robert A Ganz; Bergein F Overholt; Virender K Sharma; David E Fleischer; Nicholas J Shaheen; Charles J Lightdale; Stephen R Freeman; Ronald E Pruitt; Shiro M Urayama; Frank Gress; Darren A Pavey; M Stanley Branch; Thomas J Savides; Kenneth J Chang; V Raman Muthusamy; Anthony G Bohorfoush; Samuel C Pace; Steven R DeMeester; Viktor E Eysselein; Masoud Panjehpour; George Triadafilopoulos
Journal:  Gastrointest Endosc       Date:  2008-03-19       Impact factor: 9.427

Review 9.  A cost-utility analysis of ablative therapy for Barrett's esophagus.

Authors:  John M Inadomi; Ma Somsouk; Ryan D Madanick; Jennifer P Thomas; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2009-03-06       Impact factor: 22.682
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.